Sen-Jam Pharmaceutical

Executive Summary

Sen-Jam Pharmaceutical is a private biotechnology company founded in 2020, focused on developing non-addictive treatments for pain and inflammation using its proprietary PAIR immuno-regulator platform. The platform targets systemic inflammation as a root cause of multiple chronic diseases, with pipelines addressing infectious disease, respiratory conditions, metabolic disorders, and opioid use disorder. The company has advanced to Phase 3 clinical development, indicating significant progress in validating its platform. With a strong emphasis on addressing the opioid crisis and inflammation-driven diseases, Sen-Jam aims to provide safer alternatives to current therapies. The company is headquartered in New York and remains privately held, with no disclosed funding or valuation. Its Phase 3 status and broad pipeline suggest potential for near-term value inflection points, though the lack of public financial data adds uncertainty.

Upcoming Catalysts (preview)

• Q3 2026Phase 3 top-line data readout for lead candidate in pain/inflammation45% success
• Q4 2026FDA meeting or guidance on regulatory pathway for lead indication70% success
• Q2 2027Series B or C financing round to fund pipeline advancement60% success